This influx of money, advocates say, presents a unique opportunity for the U.S. to fund treatment solutions for substance use disorder and the overdose epidemic.
Almost four years after becoming the first state to cap insulin copayments, Colorado may limit what consumers pay for epinephrine autoinjectors, also known as EpiPens, which treat serious allergic reactions.